Anti-hypertensives Associated with Survival in Cancer Patients Receiving Immunotherapy: New Evidence from a Real-world Cohort Study and Meta-analysis

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2024 Nov 12

PMID 39529892

Authors

Ping Ma

Zhihuan Zhang

Mengying Qian

Hao Jiang

Yu Zhao

Qing Shan

Xia Liu

Tianming Yao

Jinmin Guo

Affiliations

Soon will be listed here.

Abstract

Background: The efficacy of immune checkpoint inhibitors (ICIs) in cancer patients taking anti-hypertensive drugs is still not well established.

Objective: To elucidate the effect of anti-hypertensive drugs on the clinical outcome of cancer patients receiving immunotherapy.

Design: A retrospective cohort study and meta-analysis.

Method: We conducted a real-world retrospective study of cancer patients treated with immunotherapy at two tertiary centers between January 2019 and June 2023, with primary outcomes being overall survival (OS) and progression-free survival (PFS). In addition, we performed a meta-analysis to synthesize currently relevant clinical studies.

Results: A retrospective clinical study of 336 patients from 2 centers suggested that the use of anti-hypertensive drugs was related to a preferable OS (hazard ratio (HR) = 0.55, 95% confidence interval (CI): 0.33-0.90) compared to non-users. For PFS, no significant correlation was detected (HR = 0.71, 95% CI: 0.49-1.03). Further analysis revealed that renin-angiotensin system inhibitor (RASi) and calcium channel blocker (CCB) have a synergistic effect with ICIs. In addition, subgroup analysis found that the benefits of RASi or CCB in combination with ICIs are greater in women or patients ⩾65 years of age. There was better disease control in lung cancer patients using RASi, and a significantly longer OS was observed in patients with gastrointestinal tumors taking CCB. Meta-analysis suggested that anti-hypertensive drugs were associated with improved OS, but only the combination of RASi and immunotherapy showed a synergistic effect. No significant correlation with OS was found for other anti-hypertensive drugs, and there was no overall positive effect on PFS.

Conclusion: Our study found that use of anti-hypertensive drugs, particularly RASi or CCB, was associated with improved OS in patients undergoing immunotherapy. The synergistic effects of RASi or CCB with ICIs were more pronounced in females or elderly. RASi or CCB exhibited different benefits in various types of tumors. These findings provide valuable insights for treating cancer patients with hypertension.

References

Drobni Z, Michielin O, Quinaglia T, Zlotoff D, Zubiri L, Gilman H . Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors. Eur J Cancer. 2022; 163:108-118. PMC: 9618285. DOI: 10.1016/j.ejca.2021.12.024. View

Jain R, Skelton Iv W, Pond G, Naqvi M, Kim Y, Curran C . Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma. Clin Genitourin Cancer. 2021; 19(6):540-546. PMC: 8526625. DOI: 10.1016/j.clgc.2021.04.002. View

Grimm M, Leucht K, Grunwald V, Foller S . New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. J Clin Med. 2020; 9(2). PMC: 7074019. DOI: 10.3390/jcm9020565. View

Giordan Q, Salleron J, Vallance C, Moriana C, Clement-Duchene C . Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors. Front Immunol. 2021; 12:716317. PMC: 8578856. DOI: 10.3389/fimmu.2021.716317. View

Failing J, Finnes H, Kottschade L, Allred J, Markovic S . Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma. Melanoma Res. 2016; 26(6):609-615. DOI: 10.1097/CMR.0000000000000299. View

Nuzzo P, Adib E, Weise N, Curran C, Stewart T, Freeman D . Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors. Clin Genitourin Cancer. 2022; 20(4):301-306. PMC: 10013974. DOI: 10.1016/j.clgc.2022.04.012. View

Tozuka T, Yanagitani N, Yoshida H, Manabe R, Ogusu S, Tsugitomi R . Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients. Anticancer Res. 2021; 41(4):2093-2100. DOI: 10.21873/anticanres.14980. View

Hargadon K, Johnson C, Williams C . Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018; 62:29-39. DOI: 10.1016/j.intimp.2018.06.001. View

van Dorst D, Dobbin S, Neves K, Herrmann J, Herrmann S, Versmissen J . Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. Circ Res. 2021; 128(7):1040-1061. PMC: 8011349. DOI: 10.1161/CIRCRESAHA.121.318051. View

10.

Liao Y, Fang B, Wu Q, Dong W, Deng G . Verapamil modulates NFAT2 to inhibit tumor growth and potentiates PD1ab immune checkpoint inhibitor therapy in cervical cancer treatment. J Recept Signal Transduct Res. 2023; 43(4):93-101. DOI: 10.1080/10799893.2023.2291562. View

11.

Shiravand Y, Khodadadi F, Kashani S, Hosseini-Fard S, Hosseini S, Sadeghirad H . Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022; 29(5):3044-3060. PMC: 9139602. DOI: 10.3390/curroncol29050247. View

12.

Oh M, Guzner A, Wainwright D, Mohindra N, Chae Y, Behdad A . The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Clin Lung Cancer. 2020; 22(1):e57-e62. PMC: 7785632. DOI: 10.1016/j.cllc.2020.07.016. View

13.

Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis D, Aerts J . Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021; 9(4). PMC: 8031700. DOI: 10.1136/jitc-2021-002421. View

14.

Pinter M, Jain R . Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med. 2017; 9(410). PMC: 5928511. DOI: 10.1126/scitranslmed.aan5616. View

15.

Leshem Y, Etan T, Dolev Y, Nikolaevski-Berlin A, Miodovnik M, Shamai S . The prognostic value of beta-1 blockers in patients with non-small-cell lung carcinoma treated with pembrolizumab. Int J Cardiol. 2023; 397:131642. DOI: 10.1016/j.ijcard.2023.131642. View

16.

Eng L, Sutradhar R, Niu Y, Liu N, Liu Y, Kaliwal Y . Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. J Clin Oncol. 2023; 41(17):3122-3134. DOI: 10.1200/JCO.22.00074. View

17.

Bruera S, Suarez-Almazor M . The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. Front Oncol. 2022; 12:928390. PMC: 9445222. DOI: 10.3389/fonc.2022.928390. View

18.

Kwapisz D . Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol Immunother. 2020; 70(3):607-617. PMC: 10992894. DOI: 10.1007/s00262-020-02736-z. View

19.

Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V . Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. Eur J Cancer. 2020; 142:18-28. DOI: 10.1016/j.ejca.2020.09.033. View

20.

Nakamura K, Yaguchi T, Ohmura G, Kobayashi A, Kawamura N, Iwata T . Involvement of local renin-angiotensin system in immunosuppression of tumor microenvironment. Cancer Sci. 2017; 109(1):54-64. PMC: 5765296. DOI: 10.1111/cas.13423. View